Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer.
Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg HC, Harbeck N, Bartsch R, Schneeweiss A, Ettl J, Würstlein R, Krug D, Taran FA, Lüftner D, Stickeler E. Lux MP, et al. Among authors: hartkopf ad. Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):664-672. doi: 10.1055/a-2074-0125. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37916184 Free PMC article.
Oncolytic virotherapy of gynecologic malignancies.
Hartkopf AD, Fehm T, Wallwiener D, Lauer U. Hartkopf AD, et al. Gynecol Oncol. 2011 Feb;120(2):302-10. doi: 10.1016/j.ygyno.2010.10.031. Epub 2010 Dec 8. Gynecol Oncol. 2011. PMID: 21145097 Review.
Oncolytic virotherapy of breast cancer.
Hartkopf AD, Fehm T, Wallwiener D, Lauer UM. Hartkopf AD, et al. Gynecol Oncol. 2011 Oct;123(1):164-71. doi: 10.1016/j.ygyno.2011.06.021. Epub 2011 Jul 20. Gynecol Oncol. 2011. PMID: 21764108 Review.
HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD, Banys M, Fehm T. Hartkopf AD, et al. Recent Results Cancer Res. 2012;195:203-15. doi: 10.1007/978-3-642-28160-0_19. Recent Results Cancer Res. 2012. PMID: 22527508 Review.
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN. Wallwiener M, et al. Among authors: hartkopf ad. Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28. Breast Cancer Res Treat. 2013. PMID: 23271327 Clinical Trial.
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Röhm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, Walter C, Neubauer H, Wallwiener D, Fehm T. Hartkopf AD, et al. Breast Cancer Res Treat. 2013 Apr;138(2):509-17. doi: 10.1007/s10549-013-2470-9. Epub 2013 Mar 15. Breast Cancer Res Treat. 2013. PMID: 23494674
Circulating tumor cells in breast cancer.
Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, Hartkopf A, Fehm T. Banys M, et al. Clin Chim Acta. 2013 Aug 23;423:39-45. doi: 10.1016/j.cca.2013.03.029. Epub 2013 Apr 24. Clin Chim Acta. 2013. PMID: 23623805 Review.
232 results